Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results
- PMID: 16002501
- DOI: 10.1097/01.RVI.0000161142.12822.66
Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results
Abstract
Purpose: Responses to liver-directed therapy with yttrium 90 microspheres (SIR-Spheres) and adjuvant intraarterial chemotherapy have occurred in patients with unresectable colorectal hepatic metastases who had received less than one chemotherapy regimen. Now, SIR-Spheres are being used to treat patients with advanced disease who have received multiple chemotherapy regimens. A retrospective analysis was performed to determine the technical feasibility of SIR-Sphere treatment in this population.
Materials and methods: The medical records of 12 patients with hepatic metastatic disease and intrahepatic progression after multiple chemotherapy regimens for unresectable colorectal hepatic metastases who were treated with one or two infusions of SIR-Spheres were retrospectively analyzed for demographics, tumor characteristics, treatment details, response, and survival.
Results: Twelve patients underwent 17 outpatient infusions of SIR-Spheres. Percent hepatic tumor volume was less than 25% in four patients, 25%-50% in three, and more than 50% in five. Treatment in 11 patients with bilobar disease was accomplished via single infusions in six cases and sequential unilobar infusions in five patients. A single infusion was used to treat unilobar disease in the remaining patient. Median prescribed dose was 39.6 mCi (mean, 37.2 mCi; range, 17-67.5 mCi); the prescribed dose exceeded the delivered dose in six infusions (35%) as a result of embolic arterial occlusion. Radiologic response was stable in five of nine patients. Carcinoembryonic antigen levels decreased in four of seven patients. Four patients received chemotherapy concomitantly or after completion of treatment. Gastric ulceration in one patient was managed nonoperatively. Median survival times from diagnosis and treatment were 24.6 and 4.5 months, respectively.
Conclusions: Treatment with SIR-Spheres induces responses in patients with advanced unresectable colorectal hepatic metastases after multiple chemotherapy regimens. Inability to deliver the prescribed dose is related to the embolic effect of SIR-Spheres.
Similar articles
-
A multicentric phase II clinical trial on intra-arterial hepatic radiotherapy with 90yttrium SIR-spheres in unresectable, colorectal liver metastases refractory to i.v. chemotherapy: preliminary results on toxicity and response rates.In Vivo. 2006 Nov-Dec;20(6A):711-4. In Vivo. 2006. PMID: 17203751 Clinical Trial.
-
Selective internal radiation therapy with 90Y microspheres for colorectal liver metastases: single-centre experience with 100 patients.ANZ J Surg. 2006 Aug;76(8):696-703. doi: 10.1111/j.1445-2197.2006.03834.x. ANZ J Surg. 2006. PMID: 16916386
-
Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases.J Vasc Interv Radiol. 2008 Aug;19(8):1187-95. doi: 10.1016/j.jvir.2008.05.013. Epub 2008 Jun 27. J Vasc Interv Radiol. 2008. PMID: 18656012
-
Yttrium-90 labelled resin microspheres for treatment of primary and secondary malignant liver tumors.Q J Nucl Med Mol Imaging. 2009 Jun;53(3):317-24. Q J Nucl Med Mol Imaging. 2009. PMID: 19521311 Review.
-
Internal radiation therapy for patients with primary or metastatic hepatic cancer: a review.Cancer. 1998 Nov 1;83(9):1894-907. Cancer. 1998. PMID: 9806647 Review.
Cited by
-
Prophylactic Medication during Radioembolization in Metastatic Liver Disease: Is It Really Necessary? A Retrospective Cohort Study and Systematic Review of the Literature.Diagnostics (Basel). 2023 Dec 12;13(24):3652. doi: 10.3390/diagnostics13243652. Diagnostics (Basel). 2023. PMID: 38132236 Free PMC article.
-
Transarterial Radioembolization for Management of Hepatocellular Carcinoma.Oncologist. 2024 Feb 2;29(2):117-122. doi: 10.1093/oncolo/oyad327. Oncologist. 2024. PMID: 38128565 Free PMC article.
-
Identifying Optimal Surgical Intervention-Based Chemotherapy for Gastric Cancer Patients With Liver Metastases.Front Oncol. 2021 Nov 29;11:675870. doi: 10.3389/fonc.2021.675870. eCollection 2021. Front Oncol. 2021. PMID: 34912701 Free PMC article.
-
Biliary-Caval Fistula following Y90 Radioembolization.Semin Intervent Radiol. 2021 Oct;38(4):488-491. doi: 10.1055/s-0041-1735605. Epub 2021 Oct 7. Semin Intervent Radiol. 2021. PMID: 34629719 Free PMC article. Review.
-
Legumain Induces Oral Cancer Pain by Biased Agonism of Protease-Activated Receptor-2.J Neurosci. 2021 Jan 6;41(1):193-210. doi: 10.1523/JNEUROSCI.1211-20.2020. Epub 2020 Nov 10. J Neurosci. 2021. PMID: 33172978 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical